Krystal Biotech, Inc. (NASDAQ:KRYS) Shares Sold by Rhumbline Advisers

Rhumbline Advisers lowered its stake in Krystal Biotech, Inc. (NASDAQ:KRYS) by 1.7% in the 4th quarter, according to its most recent filing with the SEC. The fund owned 69,136 shares of the company’s stock after selling 1,173 shares during the period. Rhumbline Advisers’ holdings in Krystal Biotech were worth $10,831,000 as of its most recent SEC filing.

Other institutional investors have also modified their holdings of the company. State Street Corp grew its stake in Krystal Biotech by 9.0% in the third quarter. State Street Corp now owns 1,452,811 shares of the company’s stock worth $264,455,000 after purchasing an additional 119,936 shares in the last quarter. Geode Capital Management LLC raised its stake in Krystal Biotech by 2.0% during the third quarter. Geode Capital Management LLC now owns 591,631 shares of the company’s stock valued at $107,714,000 after buying an additional 11,411 shares in the last quarter. Franklin Resources Inc. lifted its holdings in Krystal Biotech by 34.2% during the 3rd quarter. Franklin Resources Inc. now owns 243,760 shares of the company’s stock worth $43,774,000 after buying an additional 62,178 shares during the last quarter. Charles Schwab Investment Management Inc. grew its position in shares of Krystal Biotech by 9.0% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 240,216 shares of the company’s stock worth $43,727,000 after acquiring an additional 19,777 shares in the last quarter. Finally, Braidwell LP increased its holdings in shares of Krystal Biotech by 57.4% in the 3rd quarter. Braidwell LP now owns 168,691 shares of the company’s stock valued at $30,707,000 after acquiring an additional 61,512 shares during the last quarter. Institutional investors and hedge funds own 86.29% of the company’s stock.

Krystal Biotech Stock Performance

KRYS stock opened at $187.86 on Monday. The stock’s fifty day moving average is $157.85 and its two-hundred day moving average is $175.26. The stock has a market capitalization of $5.41 billion, a price-to-earnings ratio of 62.83 and a beta of 0.84. Krystal Biotech, Inc. has a 1 year low of $107.50 and a 1 year high of $219.34.

Krystal Biotech (NASDAQ:KRYS) last issued its quarterly earnings data on Monday, February 24th. The company reported $1.52 earnings per share for the quarter, beating the consensus estimate of $1.29 by $0.23. Krystal Biotech had a net margin of 30.69% and a return on equity of 11.41%. The firm had revenue of $91.10 million for the quarter, compared to the consensus estimate of $91.35 million. During the same period last year, the firm posted $0.30 EPS. Krystal Biotech’s quarterly revenue was up 116.4% compared to the same quarter last year. As a group, analysts predict that Krystal Biotech, Inc. will post 6.14 EPS for the current fiscal year.

Insider Activity

In related news, insider Suma Krishnan sold 25,000 shares of the firm’s stock in a transaction that occurred on Friday, December 13th. The stock was sold at an average price of $164.78, for a total value of $4,119,500.00. Following the sale, the insider now directly owns 1,475,882 shares in the company, valued at $243,195,835.96. This trade represents a 1.67 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Corporate insiders own 14.10% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on the company. Citigroup raised their price objective on Krystal Biotech from $206.00 to $215.00 and gave the stock a “neutral” rating in a research note on Thursday. Cantor Fitzgerald reissued an “overweight” rating and set a $215.00 target price on shares of Krystal Biotech in a report on Thursday. HC Wainwright reaffirmed a “buy” rating and issued a $221.00 price target on shares of Krystal Biotech in a report on Wednesday, February 19th. Finally, Chardan Capital boosted their price objective on shares of Krystal Biotech from $212.00 to $218.00 and gave the company a “buy” rating in a research report on Thursday. One investment analyst has rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, Krystal Biotech presently has a consensus rating of “Buy” and a consensus target price of $210.00.

Krystal Biotech Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).